ALT-01 not checked

Altis Medicines, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Autoimmune Disease
Main trialPhase 1
“The primary objective of the study is to evaluate the safety and tolerability of ALT-01 in healthy participants”In the company’s words, NCT07865442 on ClinicalTrials.gov

Other drugs for Autoimmune Disease

All 403 drugs for Autoimmune Disease

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Sep 2027 First in Human Study of ALT-01 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ALT-01

Following is part of Solo: you see every change to ALT-01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in